Xiang (Rita) Li

Associate, Shanghai



Rita Li is an associate in the Mergers & Acquisitions Practice Group, based in Shanghai.

Rita's experience includes advising publicly listed companies, privately-held corporates and private equity firms across a broad spectrum of industries on domestic and cross-border share and business transfers, joint ventures, general corporate advisory work, schemes of transfer of insurance business and corporate restructuring.

Bars and Courts
New York State Bar
People's Republic of China (non-practicing)
Columbia University
Internation Law
Fudan University
International Economic Law
Shanghai University of International Business and Economics


Mergers & Acquisitions

  • Huhtamaki Oyj, a key global provider of sustainable packaging solutions for billions of consumers around the world, on its €27 million acquisition of business of Jiangsu Hihio-art Packaging Co., Ltd., a leading manufacturer of paper bags, wraps and folding carton packaging in China.
  • Magna International Inc., a leading manufacturer and supplier of seating systems, mechanism and hardware solutions, on its acquisition of a majority stake in HLZX Group, a leading automotive seats supplier to Chinese automakers.
  • Bright Scholar, the largest operator of international and bilingual K-12 schools in China, on its US$195 million acquisition of CATS Colleges Holdings Limited, an international school network with a platform of campuses located across the United Kingdom, the United States, Canada, and China.

Private Equity

  • BVCF, a growth capital focused private equity fund specializing in China life sciences and healthcare industry, in its US$ 20 million investment in Oculis SA, a Switzerland-based clinical stage biopharmaceutical company.
  • Schneider Electric, a global player in energy management and automation, in connection with its minority investment in Star Charge, a leading charging pole manufacturer and operator in China.
  • BVCF Management Ltd., China's first US dollar fund that focuses on life sciences and healthcare, on its US$61 million sale of its shares in Novast Holdings Limited, a China-based pharmaceutical company that develops and commercializes generic drugs for the worldwide market.